10:03 AM EST - Concordia Healthcare Corp. : announced today that its subsidiary Pinnacle Biologics Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate Photodynamic Therapy (PDT) with PHOTOFRIN® for patients with epithelioid malignant pleural mesothelioma. Concordia Healthcare Corp.
shares T.CXR are trading up $0.11 at $35.43.
